Pfizer Sees Heavy Institutional Buying Ahead of 2028 Medicare Negotiations
Pfizer’s 2026 investor activity shows heavy institutional buying while Medicare price talks loom, hinting at future revenue impacts.
2 minutes to read
Pfizer Inc
Pfizer’s 2026 Guidance Misses, Boosting Bearish Sentiment and Uncertain Growth Outlook
Pfizer’s 2026 earnings miss sparks a sharp shift to “hold” and rising bearish sentiment, as price‑control pressures and safety concerns threaten the pharma giant’s growth legacy.
3 minutes to read